Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients

Tumor Biology

Volumn 36, Issue 12, 2015, Pages 9813-9821

  Seo, An Na ^a   Park, Kyoung Un ^b   Choe, Gheeyoung ^b,c   Kim, Woo Ho ^c   Kim, Duck Woo ^b   Kang, Sung Bum ^b   Lee, Hye Seung ^b  

^a Kyungpook National University School of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Chromosome 7; Colorectal cancer; Copy number gain; MET; Silver in situ hybridization

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; SCATTER FACTOR RECEPTOR; MET PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CHROMOSOME 7 POLYSOMY; CHROMOSOME ABERRATION; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE DOSAGE; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MET GENE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RNA TRANSCRIPTION; TUMOR LOCALIZATION; CHROMOSOME 7; COLORECTAL TUMOR; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 7; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84951299606     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3726-2     Document Type: Article

References (43)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.
2. Chaput N, Svrcek M, Auperin A, Locher C, Drusch F, Malka D, et al. Tumor-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer. Br J Cancer. 2013;109(4):1013–22. doi:10.1038/bjc.2013.362.
3. Hari DM, Leung AM, Lee JH, Sim MS, Vuong B, Chiu CG, et al. AJCC cancer staging manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am Coll Surg. 2013;217(2):181–90. doi:10.1016/j.jamcollsurg.2013.04.018.
4. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15(7):2207–14. doi:10.1158/1078-0432.ccr-08-1306.
5. Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 2010;5(3):305–13. doi:10.1097/JTO.0b013e3181ce3d1d.
6. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006;12(12):3657–60. doi:10.1158/1078-0432.ccr-06-0818.
7. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 2011;25(6):1517–24. doi:10.3892/or.2011.1219.
8. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009;27(10):1667–74. doi:10.1200/jco.2008.19.1635.
9. Tanaka A, Sueoka-Aragane N, Nakamura T, Takeda Y, Mitsuoka M, Yamasaki F, et al. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer. 2012;75(1):89–94. doi:10.1016/j.lungcan.2011.06.004.
10. Jin Y, Sun PL, Kim H, Seo AN, Jheon S, Lee CT, et al. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas. Ann Surg Oncol. 2014;21(2):621–8. doi:10.1245/s10434-013-3355-1.
11. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 2012;107(2):325–33. doi:10.1038/bjc.2012.237.
12. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol. 2011;29(10):1271–9. doi:10.1200/jco.2010.31.0367.
13. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012;9(6):314–26. doi:10.1038/nrclinonc.2012.71.
14. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res. 2003;9(4):1480–8.
15. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 2008;265(2):258–69. doi:10.1016/j.canlet.2008.02.049.
16. Edge SB, Byrd DR, Compton C, Fritz A, Greene F, Trotti A. American joint committee on cancer staging manual. American Joint Committee on Cancer Staging Manual. 2010.
17. Lee HS, Cho SB, Lee HE, Kim MA, Kim JH, Park do J, et al. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res. 2007;13(14):4154–63. doi:10.1158/1078-0432.ccr-07-0173.
18. Voravud N, Shin DM, Ro JY, Lee JS, Hong WK, Hittelman WN. Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumorigenesis. Cancer Res. 1993;53(12):2874–83.
19. Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 2013. doi:10.1038/modpathol.2013.108.
20. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14(1):22–9. doi:10.1016/j.jmoldx.2011.08.002.
21. Kim MA, Jung JE, Lee HE, Yang HK, Kim WH. In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry. Hum Pathol. 2013;44(4):487–94. doi:10.1016/j.humpath.2012.06.022.
22. Choi J, Lee HE, Kim MA, Jang BG, Lee HS, Kim WH. Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization. PLoS One. 2014;9(11), e111658. doi:10.1371/journal.pone.0111658.
23. Oh JR, Kim DW, Lee HS, Lee HE, Lee SM, Jang JH, et al. Microsatellite instability testing in Korean patients with colorectal cancer. Fam Cancer. 2012;11(3):459–66. doi:10.1007/s10689-012-9536-4.
24. Kim JH, Bae JM, Kim KJ, Rhee YY, Kim Y, Cho NY, et al. Differential features of microsatellite-unstable colorectal carcinomas depending on EPCAM expression status. Korean J Pathol. 2014;48(4):276–82. doi:10.4132/KoreanJPathol.2014.48.4.276.
25. Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One. 2014;9(5), e98528. doi:10.1371/journal.pone.0098528.
26. Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. PLoS One. 2014;9(6), e99399. doi:10.1371/journal.pone.0099399.
27. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7. doi:10.1038/nature11252.
28. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A. 2009;106(17):7131–6. doi:10.1073/pnas.0902232106.
29. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, et al. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014;20(24):6336–45. doi:10.1158/1078-0432.ccr-14-1293.
30. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res. 2010;16(2):699–710. doi:10.1158/1078-0432.ccr-09-1365.
31. Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 2013;73(10):3087–96. doi:10.1158/0008-5472.can-12-3256.
32. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12(20 Pt 1):6144–52. doi:10.1158/1078-0432.ccr-05-1418.
33. Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, et al. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer. 2011;10(4):325–32. doi:10.1016/j.clcc.2011.03.028.
34. Abou-Bakr AA, Elbasmi A. c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf J Oncolog. 2013;1(14):28–34.
35. Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumor progression, metastasis, patient survival and receptor crosstalk. Int J Color Dis. 2013;28(1):9–18. doi:10.1007/s00384-012-1520-9.
36. Gao H, Guan M, Sun Z, Bai C. High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis. Tumor Biol. 2015;36(2):515–20. doi:10.1007/s13277-014-2659-5.
37. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643–55. doi:10.1093/jnci/dji112.
38. Diep CB, Parada LA, Teixeira MR, Eknaes M, Nesland JM, Johansson B, et al. Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G-banding analysis. Genes Chromosomes Cancer. 2003;36(2):189–97. doi:10.1002/gcc.10162.
39. Toffalorio F, de Marinis F, Conforti F, Spitaleri G, Catania C, Noberasco C, et al. Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors. J Thorac Oncol. 2015;10(2):392–6. doi:10.1097/jto.0000000000000355.
40. Li YH, Wang F, Shen L, Deng YM, Shao Q, Feng F, et al. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. Clin Cancer Res. 2011;17(2):382–90. doi:10.1158/1078-0432.ccr-10-0208.
41. Seo AN, Jin Y, Lee HJ, Sun PL, Kim H, Jheon S, et al. FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer. Virchows Arch. 2014;465(5):547–58. doi:10.1007/s00428-014-1634-2.
42. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, et al. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol. 2002;15(12):1374–80. doi:10.1097/01.mp.0000039571.02827.ce.
43. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol. 2008;18(2):89–97. doi:10.1016/j.semradonc.2007.10.006.